>100 250 2c 5-Cl 3-OH >100 >100 >100 ≥ 500 2d-Ac 5-Cl 4-OAc >100 >100 >100 250 2d 5-Cl 4-OH >100 >100 >100 ≥ 500 2e 5-Cl 2-OCH3 >100 >100 >100 ≥ 500 2f 5-Cl 3-OCH3 >100 >100 >100 ≥ 500 2g 5-Cl 4-OCH3 >100 >100 >100 ≥ 500 2h 5-Cl 4-CH3 6.25 >100 >100 ≥ 500 2i 5-Cl 4-Et 3.13 >100 >100 ≥ 500 2j 5-Cl 2-Cl >100 >100 >100 ≥ 500 2k 5-Cl 3-Cl >100 >100 >100 ≥ 500 2l 5-Cl 4-Cl >100 >100 >100 ≥ 500 2m 5-Cl 4-Br >100 >100 >100 ≥ 500 2n 5-Cl 3-CF3 25 >100 >100 ≥ 500 3a 6-Cl H >100 a >100 a >100 a ≥ 500 a 3b 6-Cl 2-OH >100 >100 >100 250 3e 6-Cl 2-OCH3 >100 >100 >100 ≥ 500 3f 6-Cl 3-OCH3 50 a 100 a 100 a ≥ 500 a 3g 6-Cl 4-OCH3 >100 >100 >100 ≥ 500 a 3h 6-Cl 4-CH3 >100 a >100 a >100 a ≥ 500 a 3i 6-Cl 4-Et >100 a >100 a >100 a ≥ 500 a 3j 6-Cl 2-Cl >100 >100 >100 ≥ 500 3k 6-Cl 3-Cl >100 a >100 a >100 a ≥ 500 a 3l 6-Cl 4-Cl >100 a >100 a >100 a ≥ 500 a 3n 6-Cl 
Results

Strain
Tested compound (lab code / publication code) -MIC (µM) SA 24 h >500 >500 >500 >500 >500 >500 >500 >500 >500
48 h >500 >500 >500 >500 >500 >500 >500 >500 >500
MRSA 24 h >500 >500 >500 >500 >500 >500 >500 >500 >500
SE
24 h >500 >500 >500 >500 >500 >500 >500 >500 500 48 h >500 >500 >500 >500 >500 >500 >500 >500 500 EF 24 h >500 >500 >500 >500 >500 >500 >500 >500 >500
EC
24 h >500 >500 >500 >500 >500 >500 >500 >500 >500
KP
KP-E 24 h >500 >500 >500 >500 >500 >500 >500 >500 >500 48 h >500 >500 >500 >500 >500 >500 >500 >500 >500
PA 72 h >500 >500 >500 >500 >500 >500 >500 >500 500 120 h >500 >500 >500 >500 >500 >500 >500 >500 500
Strain
Tested compound ( >125  >500  >125  >500  >125  >500  >125  >125  >125   48 h  >125  >500  >125  >500  >125  >500  >125  >125  >125   SE   24 h  >125  >500  >125  500  >125  >500  >125  >125  >125   48 h  >125  >500  >125  500  >125  >500  >125  >125  >125   EF   24 h  >125  >500  >125  >500  >125  >500  >125  >125  >125   48 h  >125  >500  >125  >500  >125  >500  >125  >125  >125   EC   24 h  >125  >500  >125  >500  >125  >500  >125  >125  >125   48 h  >125  >500  >125  >500  >125  >500  >125  >125  >125   KP   24 h  >125  >500  >125  >500  >125  >500  >125  >125  >125   48 h  >125  >500  >125  >500  >125  >500  >125  >125  >125   KP-E 24 h   >125  >500  >125  >500  >125  >500  >125  >125  >125   48 h  >125  >500  >125  >500  >125  >500  >125  >125  >125   PA   72 h  >125  >500  >125  >500  >125  >500  >125  >125  >125   120 h  >125  >500  >125  >500  >125  >500  >125  >125  >125 Strain Tested compound (lab code / publication code) -MIC (µM) OV-2A  OV-3  OV-4  OV-13  JZ-AM23 JZ-AM25 JZ-AM27  2j  2k  2l  2m  3e  3j  3k   SA   24 h  62.5  >125  >125  >125  >500  >500  >125   48 h  62.5  >125  >125  >125  >500  >500  >125   MRSA 24 h   >500  >125  >125  >125  >500  >500  >125   48 h  >500  >125  >125  >125  >500  >500  >125   SE   24 h  >500  >125  >125  >125  >500  >500  >125   48 h  >500  >125  >125  >125  >500  >500  >125   EF   24 h  >500  >125  >125  >125  >500  >500  >125 48 h >500 >125 >125 >125 >500 >500 >125 Compounds 1h, 1i, 2n, 3a, 3f, 3g, 3k, 3l, and 3n precipitated during the preparation of the basic solution of the compound and therefore the testing was discontinued. CA 24 h 500 >500 >500 >500 >500 >500 >500 >500 500 48 h >500 >500 >500 >500 >500 >500 >500 >500 500 CT 24 h >500 >500 >500 >500 >500 >500 >500 >500 >500
EC
Strain
CK
CG
TA 24 h >500 >500 >500 >500 >500 >500 >500 >500 >500
AF
24 h >500 >500 >500 >500 >500 >500 >500 >500 >500 48 h >500 >500 >500 >500 >500 >500 >500 >500 >500
LC
TI
72 h >500 500 >500 >500 >500 >500 >500 >500 >500 120 h >500 500 >500 >500 >500 >500 >500 >500 >500 Compounds 1h, 1i, 2n, 3a, 3f, 3g, 3k, 3l, and 3n precipitated during the preparation of the basic solution of the compound and therefore the testing was discontinued. 147.98, 142.11, 140.74, 137.29, 134.26, 131.59 (q, J = 33.1 Hz), 130.54, 129.63, 129.19 (q, J = 3.6 Hz) 37, 148.26, 142.26, 141.96, 136.46, 133.32, 132.58, 128.61, 128.40 . IR (ATR-Ge, cm -1 ): 3342; 1655 (C=O, amide); 1541; 1511; 1484; 1340; 1249; 1131; 1103; 1020; 710; 690; 661. Anal. calcd. for C11H8ClN3O (MW 233.66): C, 56.55; H, 3.45; N, 17.98. Found: C, 56.89; H, 3.23; N, 18.22 . 165.09, 148.41, 147.90, 142.45, 142.11, 135.98, 132.51, 129.77, 128.09, 125.96, 123.45, 20.87 4 Hz, 2H, H2, H6), 6.86 (d, J = 8.4 Hz, 2H, H3, H5) . 13 C NMR (126 MHz, DMSO-d6) δ 165.77, 161.57, 148.55, 142.12, 141.53, 136.39, 130.69, 123.68, 115.22. IR (ATR-Ge, cm -1 ): 3106; 1644 (C=O, amide); 1588; 1532; 1505; 1434; 1336; 1270; 1235; 1139; 1018; 911; 843; 738; 710. Anal. calcd. for C11H8ClN3O2 (MW 249.65): C, 52.92; H, 3.23; N, 16.83. Found: C, 53.025; H, 3.445; N, 16.77. 4-((5-chloropyrazin-2-yl) (126 MHz, DMSO-d6) δ 169.07, 165.60, 153.73, 148.23, 142.27, 141.99, 136.42, 130.83, 130.05, 122.09, 21.07. IR (ATR-Ge, cm -1 ): 3396; 3090; 1761 (C=O, ester); 1683 (C=O, amide); 1535; 1497; 1348; 1171; 1136; 1016; 911; 854; 755. Anal. calcd. for C13H10ClN3O3 (MW 291.69): C, 53.53; H, 3.46; N, 14.41. Found: C, 53.92; H, 3.68; N, 14.23 . 4 Hz, 1H, H6´), 7.83 (dd, J = 7.6, 1.8 Hz, 1H, ArH), 1H, ArH), 7.24 (d, J = 8.4 Hz, 1H, ArH), 1H, ArH), 3.96 (s, 3H, OCH3) . 13 C NMR (75 MHz, DMSO-d6) δ 164. 47, 157.26, 147.55, 142.49, 141.99, 135.46, 133.82, 130.75, 121.96, 121.05, 112.58, 56.45. IR (ATR-Ge, cm -1 ): 3309; 1677 (C=O, amide); 1601; 1531; 1511; 1484; 1344; 1293; 1227; 1116; 1013; 748; 680. Anal. calcd. for C12H10ClN3O2 (MW 263.68): C, 54.66; H, 3.82; N, 15.94. Found: C, 54.48; H, 3.77; N, 15.75. N-(5-chloropyrazin-2-yl)-3-methoxybenzamide (2f 03, 159.31, 148.22, 142.24, 141.98, 136.48, 134.61, 129.76, 120.70, 118.80, 113.12, 55.55. IR (ATR-Ge, cm -1 ): 3379; 3125; 3100; 2939; 2836; 1680 (C=O, amide); 1585; 1530; 1513; 1484; 1429 1348 1287; 1272; 1257; 1143; 1048; 1017; 809; 735; 677. Anal. calcd. for C12H10ClN3O2 (MW 263.68): C, 54.66; H, 3.82; N, 15.94. Found: C, 54.65; H, 3.825; N, 15.735. N-(5-chloropyrazin-2-yl)-4-methoxybenzamide (2g , 3.82; N, 15.94. Found: C, 54.655; H, 3.855; N, 15.695 . 18, 148.88, 148.32, 142.20, 141.82, 136.41, 130.72, 128.55, 127.99, 28.27, 15.39 
Strain
4-chloro-N-(4-chlorobenzoyl)-N-(pyrazin-2-yl)benzamide (1l-SP
N-(5-chloropyrazin-2-yl)-2-hydroxybenzamide (2b
N-(5-chloropyrazin-2-yl)-2-methoxybenzamide (2e
N-(5-chloropyrazin-2-yl)-4-methylbenzamide (2h
HepG2 cytotoxicity determination
The human liver hepatocellular carcinoma cell line HepG2 (passage 32-34 for compounds 2b-Ac, 2b, 2h, and 2i; and passage 17-18 for 2d-Ac and 3n) purchased from Health Protection Agency Culture Collections (ECACC, Salisbury, UK) was routinely cultured in Minimum Essential Eagle Medium (MEM; Sigma-Aldrich) supplemented with 10% (v/v) fetal bovine serum (PAA, Austria), 1% (v/v) L-glutamine solution (Sigma-Aldrich) and 1% (v/v) non-essential amino acid solution (Sigma-Aldrich) in a humidified atmosphere containing 5% CO2 at 37 °C. For subculturing, the cells were harvested after trypsin/EDTA (Sigma-Aldrich) treatment at 37°C. To evaluate the cytotoxicity, the HepG2 cells treated with the tested substances were used as experimental groups whereas untreated HepG2 cells served as control groups.
HepG2 cells were seeded in a density of 1×10 4 cells per well on a 96-well plate. Next day (24 h after seeding) the cells were treated with tested substances dissolved in DMSO at different concentrations ranging from 0.1 to 1000 µM (depending on the solubility, see Table 2 ). Maximal incubation concentration of DMSO in a well did not exceed 1% (v/v). The treatment was carried out in triplicates in a humidified atmosphere containing 5% of CO2 at 37 °C. The controls representing 100% cell viability (untreated cells), 0% cell viability (cells treated with 10% DMSO), no-cell controls and vehiculum controls were incubated in triplicates simultaneously. After 24 h exposure to tested compounds, CellTiter 96® Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA) reagent was added to each well according to the manufacturer`s recommendations. After 2 h incubation at 37 °C in humidified, 5% of CO2 containing atmosphere, the absorbance was recorded at 490 nm. Inhibitory curves were constructed for each compound plotting incubation concentrations vs. percentage of absorbance relative to untreated control. The standard toxicological parameter IC50 was calculated by nonlinear regression analysis of the inhibitory curves using GraphPad Prism software, version 6 (GraphPad Software, Inc., CA, USA).
Confirmatory test of HepG2 cytotoxicity
The HepG2 cells (passage 35-36) were seeded in density 1×10 4 cells per well on a 96-well plate. Next day (24 h after seeding), they were treated with tested substances dissolved in DMSO (maximal incubation concentration of DMSO was 1% v/v). The tested substances were prepared according to their solubility in DMSO at incubation concentrations 0.1-500 µM (see Table 3 ). The treatment was carried out in a humidified atmosphere containing 5% CO2 at 37 °C in triplicates for 24 h and 48 h. The controls representing 100% cell viability, 0% cell viability (the cells treated with 10% DMSO and the cells treated with Lysis Solution 1:25), no-cell controls and vehiculum controls were incubated in triplicates simultaneously. After 24 h exposure, the reagent from the kit CellTox™ Green Cytotoxicity Assay (Promega, Madison, WI, USA) was prepared and added according to the recommendation of the manufacturer. After 15 min incubation at room
